Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII.
about
CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.Quantitative clinical characteristics of 53 patients with MPS VII: a cross-sectional analysis.Nanotechnology applied to treatment of mucopolysaccharidoses.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.Evaluation of intrathecal routes of administration for adeno-associated virus vectors in large animals.Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease.Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID.Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target.AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease).Gene therapy for Mucopolysaccharidoses.Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN.Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space.Targeting Root Cause by Systemic scAAV9-h Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice
P2860
Q27333793-0CAD79EB-0644-47F4-8C33-9F20D44848AAQ38684097-D5C7990D-A8C0-47B9-B920-16F47667924FQ38850460-B9833054-7717-49B3-9469-0187451BD402Q38850942-21357AB7-793B-4F69-AF00-CF63E371597EQ38856794-FA397240-B695-4BF0-B32E-DF6752C7EC0EQ40083638-52C6C298-42F2-47B6-8E7D-4E24FFEC166CQ40191364-13B2AA48-B8B5-4606-BE17-01577C327231Q40277701-7CF6BAFA-49A5-4399-B145-6CF14186BEFEQ40360298-5BC292C4-63A1-4351-A04B-99FBDB4A2219Q45875338-BCF46C3E-1E93-4B35-A0E2-26C745E0A564Q47556407-A57CB533-311C-425D-BB06-C9B44F21B16AQ47558790-25EAAD47-FBD2-4778-8DA7-3766C706F3E8Q49600921-2519880C-901A-419F-AEA1-5743D22BF12CQ54245962-A07DAC0C-8BC7-4009-945F-7C25BE3EBB23Q58765137-1655448E-017E-4562-848B-AA08979C2F91
P2860
Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Evaluation of AAV-mediated Gen ...... nine Mucopolysaccharidosis VII
@nl
Evaluation of AAV-mediated Gen ...... ine Mucopolysaccharidosis VII.
@ast
Evaluation of AAV-mediated Gen ...... ine Mucopolysaccharidosis VII.
@en
type
label
Evaluation of AAV-mediated Gen ...... nine Mucopolysaccharidosis VII
@nl
Evaluation of AAV-mediated Gen ...... ine Mucopolysaccharidosis VII.
@ast
Evaluation of AAV-mediated Gen ...... ine Mucopolysaccharidosis VII.
@en
prefLabel
Evaluation of AAV-mediated Gen ...... nine Mucopolysaccharidosis VII
@nl
Evaluation of AAV-mediated Gen ...... ine Mucopolysaccharidosis VII.
@ast
Evaluation of AAV-mediated Gen ...... ine Mucopolysaccharidosis VII.
@en
P2093
P2860
P3181
P356
P1433
P1476
Evaluation of AAV-mediated Gen ...... ine Mucopolysaccharidosis VII.
@en
P2093
Adrien De Guilhem De Lataillade
Alexander D Yox
Charles H Vite
Christian Hinderer
Guangping Gao
Hongwei Yu
Jessica Bagel
Katherine P Ponder
Margret Casal
Mark E Haskins
P2860
P304
P3181
P356
10.1038/MT.2015.189
P407
P577
2015-10-08T00:00:00Z